AR062737A1 - Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento - Google Patents
Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamentoInfo
- Publication number
- AR062737A1 AR062737A1 ARP070104006A ARP070104006A AR062737A1 AR 062737 A1 AR062737 A1 AR 062737A1 AR P070104006 A ARP070104006 A AR P070104006A AR P070104006 A ARP070104006 A AR P070104006A AR 062737 A1 AR062737 A1 AR 062737A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- hydrogen
- haloalkyl
- cyano
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
Abstract
Composicion farmacéutica que comprende un compuesto derivado de aril-azabiciclo de formula (1) o una sal farmacéuticamente aceptable, solvato o profármaco del mismo donde R1 es hidrogeno o alquilo C1-4; R2 es un grupo A, K o W; donde A es como en formula (2), K es un grupo alfa o beta naftilo, opcionalmente sustituido con 1 o 2 grupos R18, siendo cada uno de ellos Igual o diferente; y W es como en formula (3) y donde G es un grupo heteroarilo monociclico de 5 o 6 miembros o un grupo heteroarilo bicíclico de 8 a 11 miembros; de tal forma que G puede estar sustituido con (R15)p, que puede ser igual o diferente; p es un numero entero entre 0 y 5; R3 se selecciona entre el grupo que consiste en: hidrogeno, fluor y alquilo C1-4; o corresponde a un grupo X o X1; R4 se selecciona entre el grupo que consiste en: hidrogeno, fluor y alquilo C1-4; o corresponde a un grupo X o X1; R5 es hidrogeno o alquilo C1-4; R7 es hidrogeno o alquilo C1-4; o es un grupo X, X1, X2, o X3 donde: X es como en formula (4), X1 es formula (5), X2 es formula (6) y X3 es formula (7); R6 es hidrogeno o alquilo C1-4; o es un grupo X o X1; R9 es alquilo C1-4; R10 se selecciona entre un grupo que consiste en: hidrogeno, halogeno, hidroxi, ciano, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, alcanoílo C1-4 y SF5, o corresponde a un grupo R8; R8 es un grupo heterociclo de 5-6 miembros, que puede estar sustituido con uno o dos sustituyentes seleccionados entre un grupo que consiste en: halogeno, ciano, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4 y alcanoílo C1-4; R11 se selecciona entre un grupo que consiste en hidrogeno, halogeno, hidroxi, ciano, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, alcanoílo C1-4 y SF5; o corresponde a un grupo R8; R12 se selecciona entre un grupo que consiste en: hidrogeno, halogeno, hidroxi, ciano, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, alcanoílo C1-4 y SF5; o corresponde a un grupo R8; R13 se selecciona entre un grupo que consiste en hidrogeno, halogeno, hidroxi, ciano, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, alcanoílo C1-4 y SF5; o corresponde a un grupo R8; R14 se selecciona entre un grupo que consiste en: hidrogeno, halogeno, hidroxi, ciano, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, alcanoílo C1-4 y SF5; o corresponde a un grupo R8; R15 se selecciona entre un grupo que consiste en halogeno, hidroxi, ciano, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, alcanoílo C1-4 y SF5; o corresponde a un grupo R8; R16 es H, alquilo C1-4, cicloalquilo C3-6 o cicloalquil C3-6-alquilo C1-3; R17 es hidrogeno o alquilo C1-4; R18 se selecciona entre un grupo que consiste en halogeno, ciano, alquilo C1-4; R19 es haloalquilo C1-2 n es 1 o 2; y un vehiculo farmacéuticamente aceptable. El compuesto correspondiente. Uso para la preparacion de un medicamento util para el tratamiento de una afeccion en la que es beneficiosa la inhibicion de serotonina (5-HT), dopamina (DA) y norepinefrina (NE), tal como para la depresion.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0617863A GB0617863D0 (en) | 2006-09-11 | 2006-09-11 | Chemical compounds |
| GB0617868A GB0617868D0 (en) | 2006-09-11 | 2006-09-11 | Chemical compounds |
| GB0716371A GB0716371D0 (en) | 2007-08-22 | 2007-08-22 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062737A1 true AR062737A1 (es) | 2008-11-26 |
Family
ID=38561834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104006A AR062737A1 (es) | 2006-09-11 | 2007-09-11 | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20100035914A1 (es) |
| EP (1) | EP2064186A1 (es) |
| JP (1) | JP4448198B2 (es) |
| KR (1) | KR20090064447A (es) |
| AR (1) | AR062737A1 (es) |
| AU (1) | AU2007296301A1 (es) |
| BR (1) | BRPI0716532A2 (es) |
| CA (1) | CA2662538A1 (es) |
| CL (1) | CL2007002619A1 (es) |
| CO (1) | CO6150149A2 (es) |
| CR (1) | CR10671A (es) |
| EA (1) | EA200970266A1 (es) |
| IL (1) | IL197297A0 (es) |
| MA (1) | MA30767B1 (es) |
| MX (1) | MX2009002625A (es) |
| NO (1) | NO20091099L (es) |
| PE (1) | PE20081368A1 (es) |
| TW (1) | TW200826934A (es) |
| WO (1) | WO2008031772A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009002625A (es) | 2006-09-11 | 2009-03-24 | Glaxo Group Ltd | Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas. |
| GB0716573D0 (en) * | 2007-08-24 | 2007-10-03 | Glaxo Group Ltd | Chemical compounds |
| GB0804326D0 (en) * | 2008-03-07 | 2008-04-16 | Glaxo Group Ltd | Novel compounds |
| WO2010125033A1 (en) * | 2009-04-29 | 2010-11-04 | Glaxo Group Limited | Azabicyclo[4.1.0]heptane derivatives |
| WO2010130672A1 (en) * | 2009-05-12 | 2010-11-18 | Glaxo Group Limited | Azabicyclo [4.1.0] heptane derivatives and their use as monoamine reuptake inhibitors |
| WO2010133569A1 (en) * | 2009-05-20 | 2010-11-25 | Glaxo Group Limited | Azabicyclo[4.1.0]heptane derivatives |
| WO2010146025A1 (en) * | 2009-06-17 | 2010-12-23 | Glaxo Group Limited | Tricyclic azabicyclo [4.1.0] heptane derivatives as inhibitors of serotonin, dopamine and norepinephrine re-uptake |
| PL2626350T3 (pl) | 2010-09-22 | 2015-08-31 | Eisai R&D Man Co Ltd | Związek cyklopropanu |
| DE102011100831A1 (de) | 2011-05-07 | 2012-11-08 | Studiengesellschaft Kohle Mbh | Verfahren zur Herstellung von GSK 1360707 und verwandter Verbindungen mit 6-Aryl-1-[(alkyloxy) alkyl]-3-azabicyclo[4.1.0]heptan Grundgerüst |
| AU2015336463B2 (en) | 2014-10-23 | 2020-06-18 | Eisai R&D Management Co., Ltd. | Compositions and methods for treating insomnia |
| CN116261453A (zh) | 2020-08-13 | 2023-06-13 | 勃林格殷格翰国际有限公司 | 与思觉失调症相关的认知障碍的治疗 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2008A (en) * | 1841-03-18 | Gas-lamp eok conducting gas pkom ah elevated buhner to one below it | ||
| US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
| US4131611A (en) * | 1975-07-31 | 1978-12-26 | American Cyanamid Company | Azabicyclohexanes |
| US4435419A (en) | 1981-07-01 | 1984-03-06 | American Cyanamid Company | Method of treating depression using azabicyclohexanes |
| AU672644B2 (en) | 1992-12-23 | 1996-10-10 | Neurosearch A/S | Aryl substituted heterocyclic compounds |
| TR199801641T2 (xx) * | 1996-02-22 | 1998-11-23 | Neurosearch A/S | Tropan t�revleri bunlar�n haz�rlanmas� ve kullan�m� |
| DK0975595T3 (da) * | 1997-04-07 | 2009-10-19 | Univ Georgetown | Kokainanaloger |
| US6303627B1 (en) | 1998-06-19 | 2001-10-16 | Eli Lilly And Company | Inhibitors of serotonin reuptake |
| US6372919B1 (en) | 2001-01-11 | 2002-04-16 | Dov Pharmaceutical, Inc. | (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent |
| US6569887B2 (en) | 2001-08-24 | 2003-05-27 | Dov Pharmaceuticals Inc. | (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake |
| US20060173064A1 (en) | 2001-08-24 | 2006-08-03 | Lippa Arnold S | (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ATE471320T1 (de) | 2004-02-27 | 2010-07-15 | Lilly Co Eli | 4-aminopiperidinderivate als inhibitoren der monoamin-aufnahme |
| MX2009002625A (es) | 2006-09-11 | 2009-03-24 | Glaxo Group Ltd | Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas. |
-
2007
- 2007-09-07 MX MX2009002625A patent/MX2009002625A/es unknown
- 2007-09-07 AU AU2007296301A patent/AU2007296301A1/en not_active Abandoned
- 2007-09-07 WO PCT/EP2007/059381 patent/WO2008031772A1/en active Application Filing
- 2007-09-07 CA CA002662538A patent/CA2662538A1/en not_active Abandoned
- 2007-09-07 EA EA200970266A patent/EA200970266A1/ru unknown
- 2007-09-07 KR KR1020097007365A patent/KR20090064447A/ko not_active Application Discontinuation
- 2007-09-07 JP JP2009527793A patent/JP4448198B2/ja not_active Expired - Fee Related
- 2007-09-07 BR BRPI0716532-3A2A patent/BRPI0716532A2/pt not_active IP Right Cessation
- 2007-09-07 US US12/440,852 patent/US20100035914A1/en not_active Abandoned
- 2007-09-07 US US11/851,459 patent/US7691893B2/en not_active Expired - Fee Related
- 2007-09-07 PE PE2007001202A patent/PE20081368A1/es not_active Application Discontinuation
- 2007-09-07 EP EP07803326A patent/EP2064186A1/en not_active Withdrawn
- 2007-09-10 CL CL200702619A patent/CL2007002619A1/es unknown
- 2007-09-10 TW TW096133638A patent/TW200826934A/zh unknown
- 2007-09-11 AR ARP070104006A patent/AR062737A1/es not_active Application Discontinuation
-
2009
- 2009-02-26 IL IL197297A patent/IL197297A0/en unknown
- 2009-03-10 CO CO09024346A patent/CO6150149A2/es unknown
- 2009-03-13 NO NO20091099A patent/NO20091099L/no not_active Application Discontinuation
- 2009-03-19 CR CR10671A patent/CR10671A/es not_active Application Discontinuation
- 2009-03-30 MA MA31737A patent/MA30767B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20091099L (no) | 2009-04-03 |
| JP2010502761A (ja) | 2010-01-28 |
| CA2662538A1 (en) | 2008-03-20 |
| US7691893B2 (en) | 2010-04-06 |
| CO6150149A2 (es) | 2010-04-20 |
| EP2064186A1 (en) | 2009-06-03 |
| MX2009002625A (es) | 2009-03-24 |
| US20080114049A1 (en) | 2008-05-15 |
| JP4448198B2 (ja) | 2010-04-07 |
| WO2008031772A1 (en) | 2008-03-20 |
| CR10671A (es) | 2009-04-29 |
| EA200970266A1 (ru) | 2009-08-28 |
| PE20081368A1 (es) | 2008-11-19 |
| CL2007002619A1 (es) | 2008-04-18 |
| US20100035914A1 (en) | 2010-02-11 |
| KR20090064447A (ko) | 2009-06-18 |
| AU2007296301A1 (en) | 2008-03-20 |
| TW200826934A (en) | 2008-07-01 |
| IL197297A0 (en) | 2009-12-24 |
| BRPI0716532A2 (pt) | 2013-09-24 |
| MA30767B1 (fr) | 2009-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
| AR060237A1 (es) | Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende. | |
| AR047890A1 (es) | Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3 | |
| HRP20090077B1 (hr) | Modulatori farmakokinetičkih svojstava terapeutika | |
| BR112014025564B8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| UY32884A (es) | 1-sustituido-4-(5-(fenil o heteroaril)metoxi)-pirimidin-2-il)piperazinas y piperidinas | |
| UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| CL2008001669A1 (es) | Compuestos derivados de piperidina/piperazina inhibidora de dgat-1; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de la obesidad, dislipidemia, fibrosis hepatica y diabetes tipo ii, entre otras. | |
| WO2008148868A8 (en) | Piperidine/piperazine derivatives | |
| UY30440A1 (es) | Nuevos compuestos | |
| ATE507212T1 (de) | Morpholine als 5ht2c-agonisten | |
| AR061134A1 (es) | Derivados de tioxantina | |
| AR066063A1 (es) | Derivados de triazol que son antagonistas de smo | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
| AR067770A1 (es) | Derivados de tiazol y ditiazol para el tratamiento de diabetes | |
| AR062405A1 (es) | Derivados de isoindol | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| UY30363A1 (es) | Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones | |
| ES2532084T3 (es) | Composiciones de topiramato y métodos para su uso | |
| PE20210478A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |